Novel anticancer conjugates of camptothecin and unsaturated fatty acids
A technology of unsaturated fatty acid and camptothecin, which can be used in medical preparations with non-active ingredients, medical preparations containing active ingredients, organic chemistry, etc., and can solve the problems of sensitivity to toxic and side effects of chemotherapy drugs and accelerated cycle.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0117] The synthesis of embodiment 1. compound 3
[0118] tert-butyl 4-(4-nitrobenzyl)-1-piperazinecarboxylate (3). To tert-butyl 1-piperazinecarboxylate, 1 (0.74g, 4mmol), and 4-nitrobenzyl bromide, 2 (0.86g, 4mmol) in N,N-dimethylformamide (DMF, 5mL ) was added potassium carbonate (3 g), and the reaction mixture was stirred at room temperature for 4 hours. The product was extracted with ethyl acetate (50 mL), and the organic phase was washed with water (20 mL×3). The solution was dried over sodium sulfate and the solvent was removed in vacuo. Eluting with ethyl acetate, the product was purified by column chromatography to obtain solid 3 (1.22 g, 95% yield), mp 99-100°C.
[0119] 1 H NMR (DMSO-d6): 8.21-8.19 (d, 2H, J=8.8Hz, Ar-H), 7.61-7.59 (d, 2H, J=8.0Hz, Ar-H), 3.63 (s, 2H, CH 2 ), 3.34-3.30(m, 4H, partially blurred, 2×CH 2 ), 2.35-2.32 (m, 4H, 2×CH 2 ), 1.39(s, 9H, 3×CH 3 ).Analysis(C 16 h 23 N 3 o 4 ) C, H, N.
Embodiment 2
[0120] Embodiment 2. Synthesis of compound 5
[0121] tert-butyl 4-[4-(cis 4,7,10,13,16,19-docosahexenoyl)amino]benzyl-1-piperazinecarboxylate (5). To compound 3 (0.68g, 2.1mmol) in ethyl acetate (100mL) was added 10% Pd / C (0.1g), then at 60lb / inch 2The reaction mixture was hydrogenated under pressure for 2 hours. The product was filtered and the solvent was removed in vacuo to afford amine 4 (0.6 g, 97% yield), without further purification, to amine 4 (0.6 g, 2.06 mmol) dissolved in acetonitrile (90 mL) was added cis-4,7 , 10,13,16,19-docosahexaenoic acid (DHA, 0.67g, 2.0mmol), 2-(1-benzotriazol-1-yl)-1,1,3,3-tetra methyluronium hexafluorophosphate (HBTU, 0.94 g, 2.5 mmol), and N,N-diisopropylethylamine (2.1 mL). The reaction mixture was stirred overnight. The solvent was removed in vacuo and the product was purified by column chromatography eluting with ethyl acetate to afford oil 5 (0.91 g, 73% yield).
[0122] 1 H NMR (DMSO-d6): 9.84 (s, 1H, NH), 7.53-7.51 (d, 2H, J=...
Embodiment 3
[0123] Embodiment 3. Synthesis of compound 6
[0124] 1-[4-(cis-4,7,10,13,16,19-docohexenoyl)amino]benzylpiperazine (6). Compound 5 (0.85 g, 1.4 mmol) was dissolved in ethyl acetate (10 mL), then saturated anhydrous HCl dissolved in ethyl acetate (7 mL) was added. The reaction mixture was stirred at room temperature for 30 minutes. The precipitate was filtered and washed with ethyl acetate to afford 6 (0.68 g, 90% yield). The product was used in the next reaction without purification.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More - R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com
